Clinical Implications of Cell-Free DNA in Managing BRAF V600E Mutation-Positive Colorectal Cancer
Genes · 2025
DOI: 10.3390/genes16030275 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Genes, 2025. Verfasst von Takuma Iwai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8602, Japan. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Colorectal Neoplasms, Cell-Free Nucleic Acids, Biomarkers, Tumor. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: BRAFV600E-mutant colorectal cancer (CRC) is associated with poor prognosis, and despite the introduction of BEACON therapy, significant treatment challenges remain. This study investigates the clinical utility of BRAFV600E in cell-free DNA (cfDNA BRAFV600E) as a biomarker for real-time treatment monitoring in metastatic cases and for evaluating minimal residual disease (MRD) after curative resection.
Methods
This single-center, prospective observational study included 37 patients with BRAFV600E-mutant CRC treated at Nippon Medical School Hospital between April 2017 and June 2024. Patients were divided into two cohorts: Cohort 1 (Stage IV cases): Evaluated cfDNA BRAFV600E for treatment monitoring. Cohort 2 (Stage I–III curatively resected cases): Assessed cfDNA BRAFV600E for recurrence risk prediction. Blood samples were collected before and during treatment and analyzed using droplet digital PCR (ddPCR) to measure cfDNA BRAFV600E levels.
Results
Cohort 1 (Stage IV, n = 14): Pre-treatment cfDNA BRAFV600E was detected in 93% of cases. Patients with a decrease in cfDNA BRAFV600E variant allele frequency (VAF) after chemotherapy had significantly longer overall survival (511 vs. 189 days, p = 0.03) than those without a decrease. Cohort 2 (curatively resected, n = 23): cfDNA BRAFV600E was detected in 4/23 patients (17.4%) at 1 month post-surgery. cfDNA BRAFV600E showed better recurrence prediction compared to CEA (100% vs. 18.8%, p = 0.004). Among the seven patients who experienced recurrence, those with postoperative cfDNA BRAFV600E positivity had significantly shorter disease-free survival compared to cfDNA BRAFV600E-negative patients (179 vs. 840 days, p = 0.04).
Conclusions
These findings support cfDNA BRAFV600E as a promising biomarker for monitoring treatment response and MRD detection in BRAFV600E-mutant CRC, reinforcing its role in guiding personalized treatment strategies and postoperative surveillance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterological Surgery, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8602, Japan.
ORCID-Profile: Takuma Iwai, Takeshi Yamada, Kay Uehara, Seiichi Shinji, Yasuyuki Yokoyama
Zitieren
APA
Iwai, T., Yamada, T., Uehara, K., Shinji, S., Matsuda, A., Yokoyama, Y., Takahashi, G., Miyasaka, T., & Yoshida, H. (2025). Clinical Implications of Cell-Free DNA in Managing BRAF V600E Mutation-Positive Colorectal Cancer. Genes. https://doi.org/10.3390/genes16030275
Vancouver
Iwai T, Yamada T, Uehara K, Shinji S, Matsuda A, Yokoyama Y, et al. Clinical Implications of Cell-Free DNA in Managing BRAF V600E Mutation-Positive Colorectal Cancer. Genes. 2025. doi:10.3390/genes16030275
BibTeX
@article{Iwai2025,
author = {Iwai, Takuma and Yamada, Takeshi and Uehara, Kay and Shinji, Seiichi and Matsuda, Akihisa and Yokoyama, Yasuyuki and Takahashi, Goro and Miyasaka, Toshimitsu and Yoshida, Hiroshi},
title = {Clinical Implications of Cell-Free DNA in Managing BRAF V600E Mutation-Positive Colorectal Cancer},
journal = {Genes},
year = {2025},
doi = {10.3390/genes16030275}
}
EUVIMED